NZ573031A - Compounds for the treatment of metabolic disorders - Google Patents

Compounds for the treatment of metabolic disorders

Info

Publication number
NZ573031A
NZ573031A NZ573031A NZ57303107A NZ573031A NZ 573031 A NZ573031 A NZ 573031A NZ 573031 A NZ573031 A NZ 573031A NZ 57303107 A NZ57303107 A NZ 57303107A NZ 573031 A NZ573031 A NZ 573031A
Authority
NZ
New Zealand
Prior art keywords
diabetes
treatment
compound
group
obesity
Prior art date
Application number
NZ573031A
Other languages
English (en)
Inventor
Shalini Sharma
Borstel Reid W Von
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of NZ573031A publication Critical patent/NZ573031A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ573031A 2006-06-09 2007-06-08 Compounds for the treatment of metabolic disorders NZ573031A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80433606P 2006-06-09 2006-06-09
PCT/US2007/070691 WO2007146768A2 (en) 2006-06-09 2007-06-08 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
NZ573031A true NZ573031A (en) 2011-11-25

Family

ID=38832700

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ573031A NZ573031A (en) 2006-06-09 2007-06-08 Compounds for the treatment of metabolic disorders

Country Status (12)

Country Link
US (1) US20100234464A1 (enExample)
EP (1) EP2026659A4 (enExample)
JP (1) JP5252585B2 (enExample)
KR (1) KR101391905B1 (enExample)
CN (1) CN101466266A (enExample)
AU (1) AU2007257854B2 (enExample)
CA (1) CA2654530A1 (enExample)
IL (1) IL195392A0 (enExample)
MX (1) MX2008015640A (enExample)
NZ (1) NZ573031A (enExample)
WO (1) WO2007146768A2 (enExample)
ZA (1) ZA200809774B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525982A (ja) * 2006-02-02 2009-07-16 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
WO2009091732A1 (en) * 2008-01-15 2009-07-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8829058B2 (en) * 2008-03-13 2014-09-09 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
EP4548898A1 (en) 2022-07-01 2025-05-07 The University of Tokyo Body surface ulcer healing promoting device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1695716A2 (en) * 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
RU2341513C2 (ru) * 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических заболеваний
CA2502297C (en) * 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ES2530235T3 (es) * 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
ES2353601T3 (es) * 2003-04-15 2011-03-03 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos.
CN1777576A (zh) * 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
CA2522738C (en) * 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MXPA06001963A (es) * 2003-08-20 2006-05-31 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7820721B2 (en) * 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
WO2007146768A3 (en) 2008-02-21
WO2007146768A2 (en) 2007-12-21
AU2007257854B2 (en) 2012-04-12
AU2007257854A1 (en) 2007-12-21
IL195392A0 (en) 2009-08-03
KR101391905B1 (ko) 2014-05-07
KR20090018795A (ko) 2009-02-23
US20100234464A1 (en) 2010-09-16
MX2008015640A (es) 2009-01-09
CN101466266A (zh) 2009-06-24
JP2009539877A (ja) 2009-11-19
ZA200809774B (en) 2010-10-27
JP5252585B2 (ja) 2013-07-31
EP2026659A2 (en) 2009-02-25
EP2026659A4 (en) 2010-06-30
CA2654530A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
US8044243B2 (en) Compounds for the treatment of metabolic disorders
US7645772B2 (en) Treatment of metabolic disorders
US7442796B2 (en) Compounds for the treatment of metabolic disorders
EP1633340B1 (en) Compounds for the treatment of metabolic disorders
EP1618086B1 (en) Compounds for the treatment of metabolic disorders
JP4703563B2 (ja) 代謝障害を治療するための化合物
AU2007257854B2 (en) Compounds for the treatment of metabolic disorders
HK1087040B (en) Compounds for the treatment of metabolic disorders
HK1083462B (en) Compounds for the treatment of metabolic disorders
HK1083460B (en) Compounds for the treatment of metabolic disorders
ZA200600713B (en) Device for fixing a longitudinal carrier to a bone fixing element

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed